[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Turkish Society of Colon and Rectal Surgery\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579361","can-neoadjuvant-chemoradiotherapy-be-ommited-in-mid-rectal-cancer-100579361",false,"NCT06823297","Can Neoadjuvant Chemoradiotherapy be Ommited in Mid-rectal Cancer","Can Neoadjuvant Chemoradiotherapy be Omitted in cT2N+ and cT3 Mid-rectal Cancer: A Prospective, Observational Cohort Study","CANO","Inclusion Criteria:\n\n* Pathologically confirmed rectal cancer\n* Rectal cancer within 6-12 cm from anal verge confirmed by sigmoidoscopy or located between the anorectal junction and peritoneal reflection identified by MRI\n* Clinical local staging performed by MRI\n* cT2N+, cT3N0 and cT3N+ tumors\n* Patients without mesorectal fascia involvement assessed by MRI (≤1 mm)\n* Patients without pathological (short axis ≥7 mm) lateral (extramesorectal) lymph nodes on MRI\n* Patients without EMVI on MRI\n\nExclusion Criteria:\n\n* cT4 tumors\n* Stage IV disease\n* Patients with MSI (+) in TME pathology\n* PAtients who received neoadjuvant immunotherapy\n* Emergency surgery\n* Clinical obstruction\n* Previous pelvic radiotherapy\n* Patients treated without a multidisciplinary council decision\n* Inflammatory bowel diseases (Crohn's disease, Ulcerative colitis)\n* Familial adenomatous polyposis (FAP), attenuated FAP, and other polyposis syndromes\n* Hereditary non-polyposis colorectal cancer (Lynch syndrome)\n* Synchronous colon tumors","ALL","18 Years",{"count":20,"type":21},436,"ESTIMATED","5 Years","OBSERVATIONAL","This project aims to compare the oncological and functional outcomes of patients with mid-rectal cancer who have a low risk of local recurrence (without MRF involvement) and who either receive or do not receive neoadjuvant chemoradiotherapy (nCRT).\n\nMain Question:\n\nH0: In mid-rectal cancer patients without MRF involvement (cT2N+ and cT3Nx), there is no difference in 3-year disease-free survival between direct TME and TME after nCRT.\n\nH1: In mid-rectal cancer patients without MRF involvement (cT2N+ and cT3Nx), direct TME is associated with worse 3-year disease-free survival compared to TME after nCRT.\n\nParticipants already taking both interventions as part of their regular medical care for rectal cancer will be recruited in a prospective database for 5 years.",[26,27,28],"Mid-Rectal Cancer","Rectal Cancer Stage II","Rectal Cancer Stage III",[26,30,31],"Radiotherapy","Mesorectal fascia","NOT_YET_RECRUITING","2025-06-23",{"date":35,"type":36},"2025-06-27","ACTUAL",{"date":38,"type":21},"2025-08-01",{"date":40,"type":21},"2035-08-01",{"name":42,"class":43},"Turkish Society of Colon and Rectal Surgery","OTHER",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100585464","endoscopic-submucosal-dissection-vs-transanal-endoscopic-surgery-for-rectal-neoplasia-100585464","NCT06902701","Endoscopic Submucosal Dissection vs. Transanal Endoscopic Surgery for Rectal Neoplasia","Endoscopic Submucosal Dissection vs. Transanal Endoscopic Surgery for Rectal Neoplasia: A Multicenter Prospective Observational Cohort Study","ESTER","Inclusion Criteria:\n\n* Adult patients (\\>18 years)\n* Non-pedunculated (sessile) lesions larger than 2 cm.\n* Lesions located within 15 cm from the anal verge confirmed by sigmoidoscopy or magnetic resonance imaging (MRI)\n\nExclusion Criteria:\n\n* Evidence of lymph node involvement, T2 rectal tumors, or distant metastasis on preoperative imaging modalities (MRI, ERUS, CT)\n* Previous attempt at endoscopic resection\n* Previous rectal surgery\n* Previous pelvic radiation therapy\n* Inflammatory bowel diseases (Crohn's disease, Ulcerative colitis)",{"count":54,"type":21},156,"1 Year","This prospective observational cohort study aims to compare the clinical and procedural outcomes of Endoscopic Submucosal Dissection (ESD) and Transanal Minimally Invasive Surgery (TAMIS) for the treatment of early-stage rectal neoplasia. The study will evaluate recurrence rates, en bloc resection rates, R0 resection rates, procedure time, complication rates, and length of hospital stay over a 1-year follow-up period. Data will be collected from patients treated at multiple centers with expertise in ESD and TAMIS.",[58],"Rectal Neoplasms",[60,61,62],"endoscopic submucosal dissection","transanal endoscopic surgery","early rectal neoplasms","2025-06-18",{"date":65,"type":36},"2025-06-24",{"date":67,"type":21},"2025-07-01",{"date":69,"type":21},"2028-07-01",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100591759","relief-study-resolving-fissures-with-lateral-internal-sphincterotomy-100591759","NCT06984601","RELIEF Study: Resolving Fissures With Lateral Internal Sphincterotomy","RELIEF Study: Resolving Fissures With Lateral Internal Sphincterotomy - Evaluating Function and Quality of Life: A National, Prospective Cohort Study","RELIEF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosed with chronic anal fissure (symptoms lasting more than 6 weeks)\n* Decision for lateral internal sphincterotomy (LIS) made by the treating physician\n* Able to understand and complete study-related questionnaires\n\nExclusion Criteria:\n\n* Presence of other anorectal or rectal diseases (e.g., fistula, abscess, inflammatory bowel disease)\n* History of prior anal surgery or pelvic radiation\n* Inability to comprehend study-related forms or provide informed consent",{"count":80,"type":21},300,"The goal of this observational study is to learn how a common surgery called lateral internal sphincterotomy (LIS) affects people with chronic anal fissures, a painful tear near the anus. The study will look at whether this surgery helps lower problems like pain and incontinence, and how it affects quality of life and mental health.\n\nThe main questions the study aims to answer are:\n\nDoes LIS surgery lower the rate of incontinence one year after surgery? Does it improve quality of life, reduce pain, and increase patient satisfaction?\n\nParticipants will:\n\nHave surgery for chronic anal fissure called LIS. Complete short surveys about pain and mental health at 1 week, 3 months, and 12 months.\n\nAnswer questions about bowel function, incontinence and daily life at 3 and 12 months.\n\nResearchers will follow about 300 adults at hospitals across the Turkey. This study will help improve future treatment decisions and make surgery safer and more effective.",[83],"Chronic Anal Fissure",[85,86,87],"Chronic anal fissure","Lateral internal sphincterotomy","Fecal incontinence","2025-05-21",{"date":90,"type":36},"2025-05-22",{"date":92,"type":21},"2025-06-01",{"date":94,"type":21},"2027-05-31",{"name":42,"class":43},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100590721","current-microsatellite-stability-results-in-colon-cancer-100590721","NCT06971107","Current Microsatellite Stability Results in Colon Cancer","TKRCD-MSI Study: Current Microsatellite Stability Findings in Colon Cancer - Nationwide Experience From Turkey","Inclusion Criteria:\n\nPatients who have undergone curative-intent surgery for colon adenocarcinoma between June 1, 2025, and May 31, 2026 Surgery performed at a center with \\>30 colon cancer surgeries per year Availability of MMR protein immunohistochemistry (IHC) and\u002For MSI test results from resection specimen and\u002For preoperative endoscopic biopsy Signed informed consent for participation and data collection\n\nExclusion Criteria:\n\nNon-adenocarcinoma malignancies of the colon (e.g., neuroendocrine tumors, lymphomas) Rectal cancers (defined as tumors within 15 cm of the anal verge on endoscopy or MRI) Incomplete medical or pathological records preventing classification of MMR status",{"count":104,"type":21},1500,"The goal of this prospective observational study is to learn more about how a specific type of DNA repair issue-called mismatch repair deficiency (dMMR)-affects colon cancer in people living in Turkey. The study will look at how often dMMR occurs, how it is reported, and how it relates to treatment outcomes.\n\nThe main questions it aims to answer are:\n\n* How common is dMMR in colon cancer, and does it vary by where the tumor is in the colon?\n* How often is MSI (microsatellite instability) status reported in colon cancer biopsy reports before surgery?\n* How do different types of dMMR (such as MLH1\u002FPMS2 loss, MSH2\u002FMSH6 loss, or sporadic cases) affect survival over three years?\n\nParticipants will:\n\n* Be people who had surgery for colon cancer between June 1, 2025 and May 31, 2026 at hospitals in Turkey that treat more than 30 colon cancer cases each year.\n* Have their medical and pathology data reviewed, including information about tumor location, biopsy results, surgery, and treatment.\n\nThis study will not involve any new treatments. Instead, it will use existing medical records to better understand how to improve care and identify people who may benefit from immunotherapy. Results from this study will be shared at scientific meetings and published in medical journals.",[107,108,109],"Colon Adenocarcinoma","MSI Positive Colorectal Cancer","MSI Negative Colorectal Cancer",[111,112,113,114,115,116,117],"Colorectal Neoplasms","Microstaellite Instability","DNA Mismatch Repair","Immunohistochemistry","Prognosis","Survival Analysis","Epidemiologic Methods","2025-05-06",{"date":120,"type":36},"2025-05-14",{"date":92,"type":21},{"date":123,"type":21},"2029-05-31",{"name":42,"class":43},2,""]